|
Patent landscape, scope, and claims summary: |
Analysis of Claims and Patent Landscape for US Patent 10,022,451
US Patent 10,022,451, titled "Methods of treating or preventing disease with phosphodiesterase 4 inhibitors," issued on July 17, 2018, covers compositions and methods for treating specific inflammatory and immune-related conditions using phosphodiesterase 4 (PDE4) inhibitors. This analysis dissects the patent claims, evaluates their strength, and maps the patent landscape concerning PDE4 inhibitors in disease treatments.
What Are the Core Claims of US Patent 10,022,451?
The patent’s claims focus on:
- Methodology: Administering specific PDE4 inhibitors for treating diseases such as asthma, COPD, psoriasis, and psoriatic arthritis.
- Composition: Descriptions of compounds classified as PDE4 inhibitors, including known molecules like roflumilast, apremilast, and others.
- Dosing Regimen: Treatment paradigms, including dosage ranges and treatment duration.
- Combination Therapy: Use with other therapeutic agents such as corticosteroids or biologics.
Key Claims Breakdown
| Claim Type |
Summary |
Specifics |
| Independent Claims |
Target methods of treating diseases by administering PDE4 inhibitors |
Includes compound formulas and indication classes |
| Dependent Claims |
Specify dosage ranges, formulation types, and treatment regimens |
e.g., 0.01 to 10 mg daily dosing, oral formulations, combination therapies |
| Composition Claims |
Cover specific chemical compounds as PDE4 inhibitors |
Roflumilast, apremilast, and derivatives thereof |
In total, the patent contains 22 claims: 4 independent and 18 dependent, with claims primarily directed at treatment methods and compositions.
Patent Claims: Strengths and Limitations
Strengths
- Focus on Specific Diseases: Claims explicitly target inflammatory and immune-mediated diseases, aligning with known PDE4 inhibitor indications.
- Coverage of Known Molecules: Including compounds like roflumilast and apremilast, which are commercially approved, provides a broad protective scope for dosing and combination methods.
Limitations
- Scope of Chemical Entities: The claims largely encompass known PDE4 inhibitors, possibly subjecting them to prior art challenges.
- Method of Treatment: Method claims are inherently harder to enforce across different jurisdictions due to legal standards on patentability of methods.
- Lack of Novelty in Composition: Descriptions focus on established molecules, which may limit innovation claims unless specific new uses or formulations are disclosed.
Potential Challenges
- Prior Art: Multiple patents exist on PDE4 inhibitors and their use for inflammatory conditions, e.g., US Patent 5,952,291 (Roflumilast composition) and US Patent 8,898,156 (methods related to PDE4 inhibition in inflammatory diseases).
- Obviousness: The use of known PDE4 inhibitors for approved indications may be considered obvious, especially if treatment regimens correspond to standard dosing schemes.
Patent Landscape Analysis
Prior Art and Related Patents
| Patent or Patent Family |
Focus |
Filing Date |
Status |
Relevance |
| US Patent 5,952,291 |
Roflumilast composition |
1997 |
Issued |
Foundational, prior to patent 10,022,451, establishing PDE4 inhibitor use |
| US Patent 8,898,156 |
Methods of treating inflammation |
2011 |
Issued |
Contains similar disease claims, potential overlap |
| WO Patent Application 2014001234 |
Composition and dosing for PDE4 inhibitors |
2014 |
Pending |
May affect enforcement if claims are broader |
Key Players in the Patent Ecosystem
- Cephalon, Inc. / Teva Pharmaceuticals hold early patents on PDE4 inhibitors, including roflumilast.
- Ligand Pharmaceuticals and Boehringer Ingelheim possess patents on novel PDE4 inhibitor compounds and uses.
- Patent expiration cycles threaten early patents, with key PDE4-related patents expiring within the next five years.
Freedom-to-Operate (FTO) Considerations
- The overlapping claims with known compositions and methods necessitate thorough clearance searches.
- The existence of broad claims on known molecules limits enforcement unless patent claims are narrowly construed or they specify unique aspects.
Market Implications
- The patent provides enforceable rights through at least 2030 in core indications, mainly in the US.
- Competition from generic versions of roflumilast and apremilast post-expiry may diminish exclusivity.
- Additional patent filings on novel formulations, delivery systems, and combination use could extend patent life and market share.
Closing Observations
| Aspect |
Insight |
| Claim breadth |
Focused on known PDE4 molecules; potential validity challenges for obviousness |
| Patent constraints |
Method claims face legal scrutiny, composition claims benefit from known molecules but risk prior art references |
| Landscape |
Dominated by early patents on PDE4 compounds, with recent filings focusing on formulations and combination therapies |
Key Takeaways
- US Patent 10,022,451 strengthens intellectual property around PDE4 inhibitors for inflammatory diseases but faces hurdles due to prior art and obviousness.
- Enforcement may primarily target specific formulations or dosing methods rather than the compounds themselves.
- The patent's value depends on how broadly claims are interpreted and potential future innovations in formulations or delivery methods.
- The expiration of foundational patents within the next five years opens opportunities for generic manufacturers.
- Companies seeking to extend patent protection should focus on novel delivery modalities, combination treatments, or newly discovered PDE4 inhibitors.
FAQs
1. Can this patent be challenged based on prior art?
Yes, given the precedence of patents on PDE4 inhibitors like roflumilast, challenges based on obviousness and prior disclosures are feasible.
2. Are method claims enforceable across international markets?
Method claims often face legal hurdles outside the US, where patentability standards differ. Enforcement varies accordingly.
3. Does the patent cover all PDE4 inhibitors?
No, it specifies certain compounds and treatment methods. It does not necessarily cover all existing PDE4 inhibitors.
4. What is the scope of potential infringement?
Infringement would primarily involve use of the claimed compounds in the specified indications or methods within the claim scope.
5. How does patent expiry affect future research?
Expiring patents open pathways for generic development, potentially reducing market exclusivity for PDE4 inhibitors.
References
- U.S. Patent and Trademark Office. (2018). Patent No. 10,022,451. Retrieved from USPTO database.
- Johnson, D. A., & Williams, I. R. (2017). Advances in PDE4 inhibitor pharmacology. Journal of Inflammation.
- Smith, R. B. (2015). Patent landscape of PDE4 inhibitors in inflammatory diseases. Intellectual Property & Innovation.
- European Patent Office. (2019). Patent landscape report on phosphodiesterase inhibitors.
More… ↓
⤷ Start Trial
|
